Hyperfine receives FDA 510(k) clearance for world's first bedside MRI system

Hyperfine Research, Inc. announced today that it has received US Food & Drug Administration 510(k) clearance for the world's first bedside Magnetic Resonance Imaging (MRI) system, clearing the way for device shipments this summer. The Hyperfine system is 20X lower cost, 35X lower power consumption, and 10X lower weight than today's fixed conventional MRI systems.

Nearly six years ago, a dream to create a portable, affordable MRI system was born. We assembled an astounding team, and they took the 10 million-fold improvement in computing power since MRI was invented and the best of the billions invested in green electronics and built something astonishing, something disruptive."  

Jonathan Rothberg, PhD, founder and chairman of Hyperfine Research

The Hyperfine point-of-care device represents multiple innovations in MRI design, architecture and workflow; more than 100 patents have been issued or are currently pending. The system is highly portable and wheels directly to the patient's bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet such as an Apple iPad®.

The Hyperfine system was designed to address the limitations of current MRI systems in order to make MRI accessible anytime, anywhere, to any patient. "More than 40 years after its first use, MRI remains a marvel. Unfortunately, it also remains inaccessible. It's time that MRI made the jump to point of need just like X-ray and ultrasound have before it," said Dr. Khan Siddiqui, Hyperfine's Chief Medical Officer. "Going beyond that, nearly 90% of the world has no access to MRI at all. With the FDA's decision, we are now ready to rewrite the rules of MRI accessibility."

In developing the system, Hyperfine performed thousands of brain scans including those within investigational partnerships at Yale New Haven University, Penn Medicine, Good Samaritan Hospital Long Island, New York Presbyterian Brooklyn Methodist Hospital, and Brown University, in addition to calling upon seminal work from the Martinos Center for Biomedical Imaging at Massachusetts General Hospital. The FDA clearance includes head imaging for patients 2 years of age and older.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Virtual Hospital becomes flagship test site for COVID-19 virus